Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Neoplasm Drug Resistance. Found 50 abstracts

no pagination
Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, Xu X, Morris J, Yin X, Wu H, Xu W, Zheng C, Karakousis GC, Amaravadi RK, Mitchell TC, Almeida FV, Xiao M, Rebecca VW, Wang YJ, Schuchter LM, Herlyn M, Murphy ME, Weeraratna AT. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular cell. 2020 Feb 06;77(3):633-644e5.
Ablain J, Xu M, Rothschild H, Jordan RC, Mito JK, Daniels BH, Bell CF, Joseph NM, Wu H, Bastian BC, Zon LI, Yeh I. Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. Science (New York, NY). 2018 Nov 30;362(6418):1055-60.   PMCID: PMC6475924
von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol. 2018 Jan 10;36(2):136-43.   PMCID: PMC6553810
Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Nov 15;123(22):4411-8.
Hou P, Wu C, Wang Y, Qi R, Bhavanasi D, Zuo Z, Dos Santos C, Chen S, Chen Y, Zheng H, Wang H, Perl A, Guo D, Huang J. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. Cancer Res. 2017 Aug 15;77(16):4402-13.   PMCID: PMC5559306
Lu H, Liu S, Zhang G, Bin W, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 Oct 05;550(7674):133-6.   PMCID: PMC5891348
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11;7(41):67495-506.   PMCID: PMC5341892
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15;75(8):1668-74.   PMCID: PMC4541796
Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res. 2015 Jan 15;17:6.   PMCID: 4336497
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T. Preclinical efficacy for AKT targeting in clear cell carcinoma of the ovary. Molecular Cancer Research. 2015 Apr;13(4):795-806.   PMCID: PMC4398602
Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015 Oct;16(13):e510-21.
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun;20(11):3023-32.   PMCID: Pmc4049169
Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical pharmacology. 2014 May;89(1):52-61.   PMCID: Pmc3983711
Teijaro CN, Munagala S, Zhao S, Sirasani G, Kokkonda P, Malofeeva EV, Hopper-Borge E, Andrade RB. Synthesis and biological evaluation of pentacyclic strychnos alkaloids as selective modulators of the ABCC10 (MRP7) efflux pump. Journal of medicinal chemistry. 2014 Dec 26;57(24):10383-90.   PMCID: PMC4281106
Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46.
von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.   PMCID: Pmc4045341
Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu QS, Singh S, Yang DH, Talele TT, Ambudkar SV, Chen ZS. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One. 2011 Jan;6(4):e19329.   PMCID: PMC3084276
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Neoplasm Drug Resistance

Neoplasm Drug Resistance metabolism genetics drug therapy Female therapeutic use antagonists & inhibitors pharmacology drug effects Male Signal Transduction Antineoplastic Agents Aged Middle Aged Adult Protein Kinase Inhibitors Mutation pathology Tumor Cell Line administration & dosage Disease-Free Survival Molecular Targeted Therapy Mice adverse effects physiology chemistry Antineoplastic Combined Chemotherapy Protocols 80 and over Aged effects Neoplastic Gene Expression Regulation Melanoma analogs & derivatives Local Neoplasm Recurrence enzymology adverse Mitogen-Activated Protein Kinase Kinases Gene Knockdown Techniques Nude Mice ras Proteins Paclitaxel therapy Proto-Oncogene Proteins B-raf Tumor Microenvironment Apoptosis Proto-Oncogene Proteins c-akt Neoplasm Proteins Treatment Outcome Ovarian Neoplasms Mitogen-Activated Protein Kinases Monoclonal Antibodies-Humanized blood Pyridines secondary Lung Neoplasms mortality Non-Small-Cell Lung Carcinoma Retreatment Adenosine Triphosphatases MAP Kinase Kinase Kinases Cell Proliferation Receptor Protein-Tyrosine Kinases TOR Serine-Threonine Kinases analysis Colorectal Neoplasms Tumor Biomarkers Maximum Tolerated Dose Proto-Oncogene Proteins c-kit Kaplan-Meier Estimate Phospholipid Transfer Proteins Wnt5A Diarrhea Alkaloids Inhibitor of Apoptosis Proteins Genomics Cimp Proto-Oncogene Proteins Lymphoma Telatinib slow-cycling phenotype Clear Cell Adenocarcinoma Platelet-Derived Growth Factor alpha Receptor basic helix-loop-helix (MYC) Strychnos Enzyme Activation Type 5 Cyclic Nucleotide Phosphodiesterases Wnt-5a Protein DNA Methylation Fatigue Skin Neoplasms Chemoradiotherapy Survival Analysis Hypotension HCT116 Cells MAP Kinase Signaling System Camptothecin surgery Intracellular Signaling Peptides and Proteins Cisplatin Phenylurea Compounds Molecular Models JNK Mitogen-Activated Protein Kinases Breast Neoplasms IGF Type 1 Receptor Hep G2 Cells Fallopian Tube Neoplasms non-Hodgkin lymphoma Small Molecule Libraries azacitidine P-Glycoprotein therapy resistance use Immunohistochemistry Piperazines Capecitabine Salvage Therapy Proportional Hazards Models Differentiation Antigens Hematopoietic Stem Cell Transplantation Ubiquitin-Protein Ligases beta Catenin Pyridazines Proto-Oncogene Proteins c-bcl-2 colorectal cancer Young Adult Multidrug Resistance-Associated Proteins Imidazoles Protein Transport Vimentin Phosphatidylinositol 3-Kinases aged microenvironment Cultured Cells therapeutic Experimental Melanoma Myeloid Leukemia-Acute myc Genes Phosphorylation Brain Neoplasms methods HEK293 Cells Cell Death Blood-Brain Barrier Sulfonamides Multiprotein Complexes STAT2 Transcription Factor Retrospective Studies hematopoietic cell transplantation (HCT) ATP-Binding Cassette Transporters Sulfones Gastrointestinal Stromal Tumors Prognosis
Last updated on Friday, August 07, 2020